NCT00800280

Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body

A Phase 1, Open-Label, Randomized, Cross-Over Study To Estimate The Effects Of Steady-State Cimetidine On The Pharmacokinetics Of A Single Dose Of PD 0332334 In Healthy Subjects

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to estimate the effects of multiple doses of cimetidine on the pharmacokinetics of a single dose of PD 0332334 and to evaluate the safety and tolerability of PD 0332334 when co-administered with cimetidine.

Detailed description

Detailed Description: Additional Study Purpose Details: Evaluate the effects of multiple doses of cimetidine on the pharmacokinetics (e.g., elimination from the body) of a single dose of PD 0332334. On February 18th 2009, a decision to terminate further development for PD 0332334 was communicated to investigators in this study. The decision to terminate this study was not based on any safety concerns.

Conditions

• Generalized Anxiety Disorder

Interventions

Type	Name	Description
DRUG	PD 0332334	Single 300 mg dose of PD 0332334 immediate release capsules administered orally
DRUG	PD 0332334	Single 300 mg dose of PD 0332334 immediate release capsules administered orally on Day 2.
DRUG	cimetidine	600 mg q 6 hours cimetidine immediate release formulation administered orally on Days 1 through 5.

Timeline

• Start date: 2009-01-01
• Primary completion: 2009-02-01
• Completion: 2009-02-01
• First posted: 2008-12-02
• Last updated: 2010-02-17

Locations

1 site across 1 country: United States